Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Sight Sciences
(NASDAQ:SGHT)
Intraday
$5.62
0
[0.00%]
After-Hours
$5.62
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$5.62
0
[0.00%]
At close: Apr 24
$5.62
0
[0.00%]
After Hours: 4:00PM EDT
Get Report
Watch
Q1 2024 Earnings in 7 days from now on Thu May 2nd, after the market close
Conference call scheduled in 7 days at 16:30 PM
Click to view the webcast
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Sight Sciences Stock (NASDAQ:SGHT)
Sight Sciences Stock (NASDAQ: SGHT)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 10, 2024
Sight Sciences Announces The Publication Of Large-Scale, Real-World MIGS Study Demonstrating The Aqueous Outflow Restorative Procedure With OMNI Surgical System Technology Is Effective At Lowering Both IOP And IOP Reducing Medications At 2 Years In Patients With Glaucoma
Benzinga Newsdesk
-
Apr 10, 2024, 4:08PM
Needham Reiterates Hold on Sight Sciences
Benzinga Newsdesk
-
Apr 10, 2024, 5:24AM
Wednesday, April 03, 2024
Sight Sciences shares are trading higher after the company announced data from studies of two of its glaucoma and dry eye technologies will be presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting.
Benzinga Newsdesk
-
Apr 3, 2024, 7:26AM
Tuesday, April 02, 2024
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
-
Apr 2, 2024, 4:31PM
Sight Sciences Announces The Results Of The 3-Year Prospective GEMINI Trial And The Cross-Over Phase Of The SAHARA RCT At The 2024 American Society Of Cataract And Refractive Surgery Annual Meeting
Benzinga Newsdesk
-
Apr 2, 2024, 4:13PM
Friday, March 08, 2024
Stifel Maintains Buy on Sight Sciences, Raises Price Target to $7
Benzinga Newsdesk
-
Mar 8, 2024, 10:47AM
Thursday, March 07, 2024
Sight Sciences Projects 2024 Revenue $81M-$85M vs $82.41M Est.,
Benzinga Newsdesk
-
Mar 7, 2024, 5:11PM
Sight Sciences: Q4 Earnings Insights
Benzinga Insights
-
Mar 7, 2024, 4:40PM
Sight Sciences Q4 2023 GAAP EPS $(0.220) Beats $(0.340) Estimate, Sales $18.800M Miss $18.926M Estimate
Benzinga Newsdesk
-
Mar 7, 2024, 4:25PM
Earnings Scheduled For March 7, 2024
Benzinga Insights
-
Mar 7, 2024, 4:49AM
Wednesday, March 06, 2024
Sight Sciences's Earnings: A Preview
Benzinga Insights
-
Mar 6, 2024, 10:02AM
Wednesday, February 14, 2024
Sight Sciences Announces European Launch Of The Ergo-Series Of The OMNI Surgical System At The ESCRS Winter Meeting
Benzinga Newsdesk
-
Feb 14, 2024, 4:37PM
Wednesday, January 24, 2024
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
-
Jan 24, 2024, 12:31PM
Monday, January 08, 2024
Sight Sciences Expects FY23 Total Revenue Of $80.9M-$81.1M (Est. $80.42M), Up 14% Y/Y At Estimated Midpoint
Benzinga Newsdesk
-
Jan 8, 2024, 4:12PM
Sight Sciences Expects Q4 Total Revenue Of $18.6M-$18.8M (Est. $18.18M), A Decrease Of 9% Y/Y At Estimated Midpoint
Benzinga Newsdesk
-
Jan 8, 2024, 4:09PM
Thursday, December 28, 2023
Sight Sciences Announces Withdrawal Of Final LCDs On Micro-Invasive Glaucoma Surgery From Five Medicare Administrative Contractors That Were Scheduled To Take Effect On January 29, 2024.
Benzinga Newsdesk
-
Dec 28, 2023, 9:16AM
Tuesday, December 26, 2023
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
-
Dec 26, 2023, 1:48PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Dec 26, 2023, 12:31PM
Sight Sciences Shares Resume Trade
Happy Mohamed
-
Dec 26, 2023, 9:52AM
Sight Sciences Shares Halted On Circuit Breaker To The Upside, Stock Now Up 40.7%
Happy Mohamed
-
Dec 26, 2023, 9:44AM
Monday, December 18, 2023
Sight Sciences Announced The Publication In Clinical Ophthalmology Of The Six-Month Primary Results From The Sahara Randomized Controlled Trial
Benzinga Newsdesk
-
Dec 18, 2023, 4:07PM
Friday, December 08, 2023
Sight Sciences Announced The Acceptance For Publication In Clinical Ophthalmology Of GEMINI 2 Trial With Long-term Clinical Outcomes For Patients Treated With The OMNI Surgical System Technology. Publication Is Currently Expected By December 31, 2023
Benzinga Newsdesk
-
Dec 8, 2023, 8:09AM
Monday, December 04, 2023
Where Sight Sciences Stands With Analysts
Benzinga Insights
-
Dec 4, 2023, 10:00AM
Morgan Stanley Maintains Equal-Weight on Sight Sciences, Raises Price Target to $4
Benzinga Newsdesk
-
Dec 4, 2023, 7:47AM
Wednesday, November 29, 2023
Chief Technology Officer at Sight Sciences Exercises Options Worth $553K
Benzinga Insights
-
Nov 29, 2023, 10:00AM
Friday, November 24, 2023
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Nov 24, 2023, 12:31PM
Why FLJ Group Shares Are Trading Higher By Around 96%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
-
Nov 24, 2023, 12:21PM
Thursday, November 09, 2023
Sight Sciences shares are trading lower after Morgan Stanley maintained an Equal-Weight rating on the stock but lowered its price target from $4 to $3.
Benzinga Newsdesk
-
Nov 9, 2023, 2:02PM
Wednesday, November 08, 2023
Morgan Stanley Maintains Equal-Weight on Sight Sciences, Lowers Price Target to $3
Benzinga Newsdesk
-
Nov 8, 2023, 4:35PM
Tuesday, November 07, 2023
Recap: Sight Sciences Q3 Earnings
Benzinga Insights
-
Nov 7, 2023, 4:20PM
Sight Sciences Q3 2023 EPS $(0.27) Beats $(0.32) Estimate, Sales $20.01M Miss $21.59M Estimate
Benzinga Newsdesk
-
Nov 7, 2023, 4:17PM
Earnings Scheduled For November 7, 2023
Benzinga Insights
-
Nov 7, 2023, 6:34AM
Friday, October 27, 2023
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
-
Oct 27, 2023, 5:31PM
Thursday, October 26, 2023
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Oct 26, 2023, 1:31PM
Why Harley-Davidson Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
-
Oct 26, 2023, 1:27PM
Sight Sciences Shares Resumed Trade
Benzinga Newsdesk
-
Oct 26, 2023, 10:07AM
Sight Sciences Shares Halted On Circuit Breaker To The Downside, Stock Now Down -40.7%
Happy Mohamed
-
Oct 26, 2023, 9:58AM
Tuesday, October 17, 2023
Sight Sciences Reaffirms FY23 Revenue Guidance Of $80M-$82M; Est. $84.99M
Benzinga Newsdesk
-
Oct 17, 2023, 4:14PM
On October 17, 2023, Sight Sciences Informed Its Employees That It Is Implementing Targeted Plan; Reduce Its Headcount By 25 Employees, Or 10% Of Its Global Workforce - Filing
Benzinga Newsdesk
-
Oct 17, 2023, 4:11PM
Thursday, October 12, 2023
Sight Sciences Announces Presentation Of Phase I Results Of The SAHARA Randomized Controlled Clinical Trial Comparing TearCare To Restasis For The Treatment Of Dry Eye Disease At The American Academy Of Optometry Annual Meeting
Benzinga Newsdesk
-
Oct 12, 2023, 4:37PM
Tuesday, October 03, 2023
Sight Sciences Announces New, Large-Scale MIGS Data From 41st Congress Of ESCRS Demonstrating TCORâ„¢ Using OMNI Surgical System Technology Is Effective At Lowering Both IOP And IOP Reducing Medications At 2 Years In Patients With Glaucoma
Benzinga Newsdesk
-
Oct 3, 2023, 8:35AM
Thursday, September 21, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Sep 21, 2023, 12:08PM
Top 4 Health Care Stocks That Could Lead To Your Biggest Gains In Q3
Lisa Levin
-
Sep 21, 2023, 5:11AM
Monday, September 18, 2023
Stifel Maintains Buy on Sight Sciences, Lowers Price Target to $5
Benzinga Newsdesk
-
Sep 18, 2023, 10:49AM
Friday, September 15, 2023
Citigroup Maintains Neutral on Sight Sciences, Lowers Price Target to $4
Benzinga Newsdesk
-
Sep 15, 2023, 10:09AM
Wednesday, September 13, 2023
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2023
Benzinga Insights
-
Sep 13, 2023, 11:00AM
10 Analysts Have This to Say About Sight Sciences
Benzinga Insights
-
Sep 13, 2023, 11:00AM
B of A Securities Downgrades Sight Sciences to Underperform, Lowers Price Target to $4.5
Benzinga Newsdesk
-
Sep 13, 2023, 9:08AM
Morgan Stanley Maintains Equal-Weight on Sight Sciences, Lowers Price Target to $4
Benzinga Newsdesk
-
Sep 13, 2023, 9:01AM
Tuesday, September 12, 2023
Crude Oil Rises 2%; Avalo Therapeutics Shares Spike Higher
Lisa Levin
-
Sep 12, 2023, 2:44PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch